Isotopia to supply MTTI with Lu-177

By staff writers

March 26, 2021 -- Isotopia Molecular Imaging announced it has inked a deal to supply biopharmaceutical company Molecular Targeting Technologies (MTTI) with its lutetium-177 (Lu-177) medical isotope for the development of new targeted radiotherapeutics.

MTTI currently has two products in development: Lu-177 EBTATE, which targets somatostatin receptors type 2 in a variety of neuroendocrine tumors, and Lu-177 EBRGD for integrin-expressing cancers in glioblastoma multiforme and non-small cell lung cancer.

The new radiotracers bind reversibly to circulating serum albumin, which enhances radiotherapeutic circulation half-life and delivers higher accumulation to targeted tumors, according to studies.

Copyright © 2021
Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking